Literature DB >> 32058041

Proteomic analysis to identify differentially expressed proteins between subjects with metabolic healthy obesity and non-alcoholic fatty liver disease.

Xianwen Yuan1, Yuanyuan Sun2, Qi Cheng3, Kai Hu4, Juan Ye5, Yinjuan Zhao6, Jing Wu7, Xiaoyan Shao3, Lei Fang3, Yitao Ding1, Xitai Sun8, Xiaolei Shi9, Bin Xue10.   

Abstract

Obese subjects with non-alcoholic fatty liver disease (NAFLD) and considered metabolically healthy have not been well differentiated. In this study, obese subjects were divided into metabolic healthy obesity (MHO) and NAFLD groups. Liver tissues were sampled from these two types of subjects undergoing bariatric surgery, and proteins in the liver tissues that expressed differently between the two groups of subjects were identified by Tandem Mass Tags (TMT) assay. Compared with the MHO group, 132 proteins were found to be upregulated and 84 proteins were found to be downregulated (mainly localized in mitochondria) in NAFLD group. The KEGG pathway analysis showed that significantly upregulated metabolic pathways include PPAR signaling, ECM-receptor interaction and oxidative phosphorylation was significantly downregulated. The GO analysis revealed that upregulated proteins were involved in extracellular structure organization, extracellular matrix organization and downregulated proteins took part in the oxidation-reduction process and so on. FBLN5 and DHRS2 were further validated by Western blot, immunohistochemistry and ELISA. All results demonstrate that FBLN5 expression was significantly upregulated but DHRS2 was significantly downregulated. SIGNIFICANCE: The variation between MHO and NAFLD was studied by mass spectroscopy to evaluate the mechanism with which MHO subjects resist the harmful effects induced by obesity.
Copyright © 2020. Published by Elsevier B.V.

Entities:  

Keywords:  Metabolic healthy obesity (MHO); Non-alcoholic fatty liver disease (NAFLD); TMT quantitative proteomics

Mesh:

Substances:

Year:  2020        PMID: 32058041     DOI: 10.1016/j.jprot.2020.103683

Source DB:  PubMed          Journal:  J Proteomics        ISSN: 1874-3919            Impact factor:   4.044


  4 in total

1.  Analysis of key genes and related transcription factors in liver fibrosis based on bioinformatic technology.

Authors:  Xue Yang; Qi-Ni Cheng; Jiang-Feng Wu; Wen-Bing Ai; Lan Ma
Journal:  Int J Clin Exp Pathol       Date:  2021-04-15

2.  Quantitative proteomics of HFD-induced fatty liver uncovers novel transcription factors of lipid metabolism.

Authors:  Shang Zhi; Zhang Congcong; Gao Zhiling; Qian Yihan; Xin Yijing; Liu Guanjie; Wang Fang; Sun Xuehua; Li Hongjie; Kong Xiaoni; Gao Yueqiu
Journal:  Int J Biol Sci       Date:  2022-05-01       Impact factor: 10.750

Review 3.  Diagnostic Modalities of Non-Alcoholic Fatty Liver Disease: From Biochemical Biomarkers to Multi-Omics Non-Invasive Approaches.

Authors:  Eirini Martinou; Marinos Pericleous; Irena Stefanova; Vasha Kaur; Angeliki M Angelidi
Journal:  Diagnostics (Basel)       Date:  2022-02-04

4.  Ex vivo gadoxetate relaxivities in rat liver tissue and blood at five magnetic field strengths from 1.41 to 7 T.

Authors:  Sabina Ziemian; Claudia Green; Steven Sourbron; Gregor Jost; Gunnar Schütz; Catherine D G Hines
Journal:  NMR Biomed       Date:  2020-08-26       Impact factor: 4.044

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.